Gregory Grahek
Acute Care · Pueblo, CONPI 1558554188
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $836 and has fallen 69.0% since, to $259 in 2025.
Across 172 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$383
- Pfizer$366
- AbbVie$355
- AstraZeneca$302
- Amgen$185
- E.r. Squibb & Sons, L.L.C.$156
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,869100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $383 |
| Pfizer | 24 | $366 |
| AbbVie | 18 | $355 |
| AstraZeneca | 17 | $302 |
| Amgen | 12 | $185 |
| E.r. Squibb & Sons, L.L.C. | 7 | $156 |
| Johnson & Johnson | 13 | $145 |
| Astellas Pharma US Inc | 5 | $104 |
| Bayer | 5 | $98 |
| Scilex Pharmaceuticals Inc. | 6 | $93 |
| Boehringer Ingelheim | 6 | $91 |
| Lilly USA, LLC | 6 | $91 |
| Sunovion Pharmaceuticals Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Merck | 2 | $32 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| GSK | 2 | $31 |
| Biogen | 2 | $30 |
| Eisai Inc. | 2 | $29 |
| Novartis | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Medtronic | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Inogen, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$2,869 in reported general payments places this provider in the 85th percentile of 239 acute care providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $149,111 |
| OzempicSemaglutide | 42 | $66,693 |
| FarxigaDapagliflozin Propanediol | 52 | $65,017 |
| JardianceEmpagliflozin | 55 | $63,849 |
| XareltoRivaroxaban | 48 | $55,396 |
| MounjaroTirzepatide | 51 | $52,315 |
| TrulicityDulaglutide | 40 | $45,779 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $34,189 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $32,703 |
| Spiriva RespimatTiotropium Bromide | 26 | $31,603 |
| Repatha SureclickEvolocumab | 23 | $17,705 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $17,552 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $12,298 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 108 | $11,933 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 341 | $7,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $366 | $149,111153 claims |
| Lilly USA, LLCMounjaro, Trulicity | $91 | $98,09491 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $91 | $95,45281 claims |
| AstraZenecaFarxiga, Symbicort, Nexium | $302 | $85,621112 claims |
| Novo NordiskOzempic, Levemir | $383 | $68,54859 claims |
| Johnson & JohnsonXarelto | $145 | $55,39648 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $31 | $46,48757 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 239 acute care providers in Colorado.
Other acute care in Pueblo
- Gregory CharlestonPueblo$12K
- Sarah GallegosPueblo$3K
- Phebe GoldenPueblo$1K
- Tiffany MorganColorado Springs$590K
- Wendy StevensCortez$57K
- Peter ByrneLone Tree$56K
- Paige YountColorado Springs$26K
- Sarah NorwoodColorado Springs$20K
- Rachele RobertsAurora$19K
- Shari Nieman CorsoLittleton$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.